COVID-19 Disruption

Read more about the impact of COVID-19 on HIV, TB and malaria services and systems for health
download in English | Français

Country-based Local Fund Agents, who monitor grant implementation and progress on behalf of the Global Fund, complete a monthly survey online to help identify potential risks and disruptions to programs. The tool is not meant to be a rigorous assessment of the country situation. The data is based on in-country stakeholder views but not on verified data. Key insights as of 1 September 2021:

Countries in lockdown: 34% of countries where the Global Fund invests are experiencing nationwide lockdowns as of 1 September, slightly down from 38% on 1 August. 22% of countries are still experiencing local restrictions that impact the programs run by the Global Fund, marking a decrease from 25% since 1 August.

Costed national plans: The share of countries with fully costed response plans in place for their COVID-19 response has remained stable. On 1 September 2021, 83% of countries had a costed response plan in place, compared to 84% on 1 July 2021, 83% on 15 November 2020, and 75% on 15 June 2020.

Disruption to health service delivery: The overall risk of disruption to malaria services remains high compared to historic levels, while the overall risk to HIV and TB services continues to decline as of 1 September. 35% of countries are reporting no or low disruption to health service delivery for malaria and HIV, compared to 28% of countries for TB. 3% of countries are experiencing very high disruption for malaria services, compared to 1% for TB services and 0% for HIV services.

Disruption to supply of key medicines: The risk trend for the supply of key HIV medicines remains relatively high but has declined as of 1 September. The risk trend for the supply of TB medicines has declined slightly, while the risk trend for the supply of malaria medicines remains stable. For all three diseases , at least half of the countries where the Global Fund invests have a minimum 6 months’ supply capacity of key medicines. As of 1 September, 6% of countries were experiencing shortages for HIV medicines, 3% were experiencing shortages for TB medicines, and 3% were experiencing shortages for malaria medicines.

Lab services: As of 1 September, 41% of countries are reporting no or low HIV and/or TB lab services disruption and 50% of countries are reporting moderate disruption, remaining stable since 1 August. The percentage of countries experiencing high HIV and/or TB lab services disruption has slightly increased from 4% on 1 August to 5%. The share of countries reporting very high disruption has remained stable at 2% since 1 July.